What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) inhibitor in the manufacture of a medicament for treating or ameliorating at least one symptom or indication of eosinophilic esophagitis (EoE) in a subject.

2. The use according to claim 1, wherein said medicament is formulated for administration to a subject having an allergic reaction to an allergen that renders the subject susceptible to EoE.

3. The use according to claim 1 wherein said medicament is formulated for administration to a subject who exhibits at least one symptom or indication of EoE, wherein the subject has an elevated level of a biomarker selected from the group consisting of esophagus eosinophils, eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, TARC, TSLP, serum ECP, and EDN.

4. The use of any one of claims 1 to 3, wherein the symptom or indication of EoE is selected from the group consisting of eosinophilic infiltration of the esophagus, thickening of the esophageal wall, food refusal, vomiting, abdominal pain, heartburn, regurgitation, dysphagia and food impaction.

5. The use according to any one of claims 1 to 4, wherein the subject exhibits an allergic reaction to a food allergen contained in a food item selected from the group consisting of a dairy product, egg, wheat, soy, corn, fish, shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple and pineapple.

6. The use according to any one of claims 1 to 4, wherein the subject exhibits an allergic reaction to a non-food allergen derived from one of dust, pollen, mold, plant, cat, dog or insect.

7. The use according to any one of claims 1 to 6, wherein the medicament is formulated to effect reduction of the level of an EoE-associated biomarker in the subject.

8. The use according to claim 7, wherein the EoE-associated biomarker is selected from the group consisting of esophagus eosinophils, eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and eosinophil-derived neurotoxin (EDN).

9. The use according to any one of claims 1 to 8, wherein the IL-4R inhibitor is an antibody or antigen-binding fragment thereof that binds IL-4R.alpha and prevents the interaction of IL-4 and/or IL-13 with a type 1 or type 2 IL-4 receptor.

10. The use of claim 9, wherein the antibody or antigen-binding fragment thereof prevents the interaction of IL-4 and IL-13 with both type 1 and type 2 IL-4 receptors.

11. The use of claim 10, wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.

12. The use of claim 11, wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1 and the LCVR comprises the amino acid sequence of SEQ ID NO: 2.

13. The use of claim 10, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and a light chain comprising the amino acid sequence of SEQ ID NO: 14.

14. The use according to any one of claims 1 to 13, wherein the IL-4R inhibitor is formulated in combination with a second therapeutic agent or therapy and wherein the second therapeutic agent or therapy is selected from the group consisting of an IL-1beta inhibitor, an IL-5 inhibitor, an IL-9 inhibitor, an IL-13 inhibitor, an IL-17 inhibitor, an IL-25 inhibitor, a TNFalpha inhibitor, an eotaxin-3 inhibitor, an IgE inhibitor, a prostaglandin D2 inhibitor, an immunosuppressant, a corticosteroid, a glucocorticoid, a proton pump inhibitor, a non-steroidal anti-inflammatory drug (NSAID), allergen removal and diet management.

15. The use according to any one of claims 1 to 14, wherein the subject, prior to or at the time of administration of the IL-4R inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis.

16. The use of claim 3, wherein the subject is selected on the basis of exhibiting ≥ 15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the treatment ("baseline").

17. The use of claim 16, wherein the subject exhibits at least 50% decrease in the number of eosinophils per hpf from baseline at day 10 following the administration of the IL-4R inhibitor.

18. The use according to any one of claims 3, 16 or 17, wherein the subject is selected on the basis of exhibiting an eotaxin-3 level of greater than about 50 pg/mL prior to or at the time of initiation of treatment ("baseline").

19. The use of claim 18, wherein the subject exhibits at least 50% decrease in eotaxin-3 level from baseline at day 10 following the administration.